Paloma Partners Management Co boosted its stake in shares of Allergan plc (NYSE:AGN) by 202.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,773 shares of the company’s stock after purchasing an additional 34,002 shares during the quarter. Paloma Partners Management Co’s holdings in Allergan were worth $8,501,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Motco acquired a new position in Allergan during the 2nd quarter valued at $29,000. Evolution Wealth Advisors LLC acquired a new position in Allergan during the 2nd quarter valued at $30,000. Berman Capital Advisors LLC raised its stake in shares of Allergan by 48.8% in the 1st quarter. Berman Capital Advisors LLC now owns 238 shares of the company’s stock valued at $34,000 after buying an additional 78 shares in the last quarter. Truewealth LLC raised its stake in shares of Allergan by 96.8% in the 2nd quarter. Truewealth LLC now owns 248 shares of the company’s stock valued at $42,000 after buying an additional 122 shares in the last quarter. Finally, Liberty Wealth Management LLC raised its stake in shares of Allergan by 35.3% in the 2nd quarter. Liberty Wealth Management LLC now owns 257 shares of the company’s stock valued at $43,000 after buying an additional 67 shares in the last quarter. Hedge funds and other institutional investors own 80.45% of the company’s stock.
Shares of AGN traded down $0.27 during trading hours on Thursday, hitting $165.73. The stock had a trading volume of 2,866,298 shares, compared to its average volume of 2,957,458. The company’s fifty day moving average is $161.09 and its two-hundred day moving average is $149.31. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.03 and a quick ratio of 0.91. Allergan plc has a 52 week low of $114.27 and a 52 week high of $197.00. The stock has a market capitalization of $54.45 billion, a price-to-earnings ratio of 9.93, a P/E/G ratio of 1.71 and a beta of 1.61.
The company also recently announced a quarterly dividend, which was paid on Friday, September 13th. Stockholders of record on Tuesday, August 13th were issued a $0.74 dividend. This represents a $2.96 annualized dividend and a dividend yield of 1.79%. The ex-dividend date was Monday, August 12th. Allergan’s payout ratio is 17.74%.
A number of equities analysts have recently issued reports on AGN shares. Cantor Fitzgerald increased their price objective on shares of Allergan from $125.00 to $165.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. UBS Group increased their price objective on shares of Allergan from $172.00 to $189.00 and gave the company a “buy” rating in a research note on Thursday, September 12th. TheStreet upgraded shares of Allergan from a “d+” rating to a “c” rating in a research note on Friday, July 12th. Guggenheim cut shares of Allergan from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 7th. Finally, Sanford C. Bernstein cut shares of Allergan from an “outperform” rating to a “market perform” rating and set a $166.08 price objective for the company. in a research note on Tuesday, July 16th. Two equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and six have given a buy rating to the stock. Allergan presently has a consensus rating of “Hold” and a consensus target price of $178.75.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.